Race Oncology
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WARace Oncology Ltd (RAC) is an Australian pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field.
The company's first important asset is a chemotherapy drug, Bisantrene, which was the subject of more than 40 phase II clinical studies. On 13 August 2019, the company announced it had secured a new patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office.
Contact Details
Level 36, 1 Macquarie Place, SYDNEY NSW 2000
02 8051 3043
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 287th | Race Oncology | 57% | 62% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Race Oncology | $4.0m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Michelle Rashford, | 01 Nov 2024 |
| NEW ROLE: Serge Scrofani, Non-Executive Director | 18 Sep 2024 |
| NEW ROLE: Pete Smith, Executive Chairman | 07 Aug 2024 |
| NEW ROLE: David Fuller, | 15 Oct 2021 |
| ECM DEAL: New deal has been added | 19 Jul 2021 |
| NEW ROLE: Borje Andersson, Chief Medical Officer | 16 Apr 2021 |
| NEW ROLE: Mary Harney, Non-Executive Director | 16 Apr 2021 |
| NEW ROLE: Gordon Beck, President & COO | 24 Nov 2020 |
| REMUNERATION UPDATE: Samar Al-Behaisi, Chief Medical Officer, Vice President of Medical Affairs | 03 Nov 2020 |
